Lewis Silkin has advised Mercia on its syndicated venture capital investment in CanSense

Lewis Silkin’s client Mercia has backed CanSense on a round of equity funding for the development of a blood test that aims to save lives by diagnosing bowel cancer at an early stage.

CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive, and less invasive than a colonoscopy procedure and more acceptable for patients than a faecal blood detection kit. It could help detect bowel cancer at an early stage when it is much easier to treat, and the chance of survival is much higher.

The Lewis Silkin team was led by Corporate Associate, Elizabeth Cotton and Corporate Partner, Geraint Tilsley.

Commenting on the deal, Lewis Silkin’s Elizabeth Cotton said:

It was great to work on our first transaction for Mercia, and all the more so because CanSense's work really will save lives..
Elizabeth Cotton